Publication | Closed Access
Intralesional Therapy With Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell Lymphoma
98
Citations
15
References
2000
Year
Intralesional rituximab therapy is a nontoxic and effective treatment for cutaneous B-cell lymphoma that deserves further investigation in larger clinical trials.
| Year | Citations | |
|---|---|---|
Page 1
Page 1